All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

tegafur 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
uridine derivatives used as antiviral agents and as antineoplastics	4398	17902-23-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tegafur ftorafur FT-207 florafur futraful	Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. Molecular weight: 200.17 Formula: C8H9FN2O3 CLOGP: -0.06 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 58.64 ALOGS: -1.16 ROTB: 1

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.62 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.95 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	8.69 hours	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	60 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP3K21,MAPK7,NTRK2,PDK1,PDK2,PIK3CD,PRKDC,STK33,TEK	20
kinase-selectivity-class	GRK2	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
March 14, 2011	EMA	Nordic Group BV
March 1, 1999	PMDA	Taiho Pharmaceutical Co, Ltd

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	83.39	48.98	27	526	94313	110494433
Bone marrow failure	65.37	48.98	20	533	57828	110530918
Disease progression	64.81	48.98	29	524	244005	110344741

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01BC03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ANTIMETABOLITES Pyrimidine analogues
ATC	L01BC53	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ANTIMETABOLITES Pyrimidine analogues
MeSH PA	D000963	Antimetabolites
MeSH PA	D000964	Antimetabolites, Antineoplastic
MeSH PA	D000970	Antineoplastic Agents
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:231911	renoprotective agent

Related Drugs by ATC class:

L01BC Pyrimidine analogues 9 drugs

azacitidinecapecitabinecarmofurcytarabinedecitabinefloxuridinefluorouracilgemcitabinetrifluridine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Malignant tumor of stomach	indication	363349007	DOID:10534
Hormone receptor pozitive breast cancer	indication	417181009
HER2-negative breast cancer	indication	767444009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.81	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D01244	KEGG_DRUG
N0000167181	NUI
C0016778	UMLSCUI
CHEBI:32188	CHEBI
S7W	PDB_CHEM_ID
CHEMBL20883	ChEMBL_ID
DB09256	DRUGBANK_ID
10513	IUPHAR_LIGAND_ID
4415	INN_ID
1548R74NSZ	UNII
5386	PUBCHEM_CID
4582	RXNORM
007248	NDDF
395897006	SNOMEDCT_US
421459003	SNOMEDCT_US
D005641	MESH_DESCRIPTOR_UI
1548R74NSZ	INXIGHT DRUGS

Pharmaceutical products:

None